Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E22.30 EPS (ttm)2.59 Insider Own0.06% Shs Outstand1.59B Perf Week0.35%
Market Cap92.03B Forward P/E14.80 EPS next Y3.90 Insider Trans20.71% Shs Float1.57B Perf Month4.49%
Income4.17B PEG2.42 EPS next Q0.77 Inst Own80.70% Short Float6.04% Perf Quarter2.30%
Sales19.26B P/S4.78 EPS this Y-23.10% Inst Trans15.91% Short Ratio7.78 Perf Half Y12.70%
Book/sh3.27 P/B17.66 EPS next Y23.74% ROA14.50% Target Price67.38 Perf Year33.52%
Cash/sh6.43 P/C8.98 EPS next 5Y9.23% ROE92.70% 52W Range42.87 - 60.02 Perf YTD12.07%
Dividend1.68 P/FCF41.34 EPS past 5Y0.00% ROI23.20% 52W High-4.65% Beta-
Dividend %2.91% Quick Ratio2.70 Sales past 5Y- Gross Margin76.40% 52W Low33.51% ATR1.05
Employees25000 Current Ratio2.80 Sales Q/Q5.00% Oper. Margin31.20% RSI (14)50.00 Volatility2.21% 1.81%
OptionableYes Debt/Eq2.83 EPS Q/Q3.00% Profit Margin21.70% Rel Volume0.68 Prev Close57.76
ShortableYes LT Debt/Eq2.77 EarningsOct 23 BMO Payout61.80% Avg Volume12.20M Price57.23
Recom1.90 SMA20-0.98% SMA503.05% SMA2009.25% Volume8,234,105 Change-0.92%
28-Jul-14Upgrade UBS Neutral → Buy $57 → $67
24-Jun-14Reiterated Argus Buy $59 → $65
06-Jan-14Reiterated UBS Neutral $46 → $56
29-Oct-13Reiterated Argus Buy $52 → $59
12-Aug-13Initiated Argus Buy $52
15-May-13Reiterated R. F. Lafferty Buy $47.90 → $61
29-Apr-13Reiterated Barclays Equal Weight $41 → $44
15-Apr-13Reiterated Barclays Equal Weight $37 → $41
01-Oct-14 03:30PM  AbbVie Announces Positive Results on Oncology Candidate Zacks
10:05AM  AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting® PR Newswire
07:00AM  Health Care: Some Healthy Bargains Still Remain Morningstar
30-Sep-14 08:54AM  AbbVie CEO Tells Employees That Shire Deal is Going Through at The Wall Street Journal
02:01AM  PRESS DIGEST- New York Times business news - Sept 30 Reuters
29-Sep-14 04:20PM  Gilead's HCV Combo Drug Harvoni Secures CHMP Backing Zacks
03:59PM  AbbVie Tell Shire Employees: The Merger Will Go On at The Wall Street Journal
03:12PM  Health care inversions in jeopardy? CNBC
03:12PM  [video] Health care inversions in jeopardy? at CNBC
28-Sep-14 10:38PM  [$$] Overheard: Investors Expect Inversion Deals to Survive at The Wall Street Journal
27-Sep-14 06:45AM  AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress PR Newswire
26-Sep-14 05:00PM  Maverick Capital starts new position in AbbVie Market Realist
03:30PM  Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Zacks
11:37AM  Jumbo M&A borrowers urged to spread financing across markets Reuters
11:30AM  Why AbbVie (ABBV) Stock Is Up Today at TheStreet
09:21AM  AbbVie Said to Weigh More Shire Financing After U.S. Rule at Bloomberg
25-Sep-14 11:03AM  AbbVie gets new approval for its drug Humira AP
08:54AM  [$$] AbbVie Gets FDA Approval on Humira for Pediatric Crohn's at The Wall Street Journal
08:00AM  AbbVie's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn's Disease PR Newswire
24-Sep-14 05:29PM  Gilead's New HIV Drug Key To Long-Term Strategy at Investor's Business Daily
05:00PM  Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug Zacks
04:30PM  Celgene's Otezla Label Expanded to Include Plaque Psoriasis Zacks
02:53PM  Shire to pay $56.5 mln to settle improper marketing probe Reuters
10:37AM  [$$] Tax Changes Dim Appeal of AbbVie-Shire Deal at The Wall Street Journal
10:28AM  [$$] Tax Changes Dim Appeal of AbbVie-Shire Deal at The Wall Street Journal
06:10AM  Never Mind What Lew or Bill Clinton or Camp Say: Opening Line at Bloomberg
23-Sep-14 06:34PM  Moody's says may review M&As if new tax rules lead to altered terms Reuters
03:57PM  Corporate inversions mean tax hit for shareholders at USA TODAY
02:12PM  Debate: Inversion policy & tax reform CNBC
02:12PM  [video] Debate: Inversion policy & tax reform at CNBC
01:53PM  Corporate inversions mean tax hit for shareholders at USA TODAY
01:09PM  Treasury inversion crackdown CNBC
01:09PM  [video] Treasury inversion crackdown at CNBC
12:59PM  The Inversion Implosion: What Happens to AbbVie, Medtronic Deals? at Barrons.com
12:49PM  Midday movers: AbbVie, Burger King, CarMax & more at CNBC
12:48PM  Treasurys new rules won't kill tax inversions: Josh Brown Yahoo Finance
12:25PM  Shares Feel The Squeeze Of Treasury's Inversion Rules at Investor's Business Daily
12:05PM  [video] Apple, Facebook, Goldman & JPMorgan Gain Despite Slipping Markets at TheStreet
11:24AM  [video] Jim Cramer's Take on Lew's Crackdown of Corporate Tax Inversions at TheStreet
11:16AM  Bank Of America Believes Anti-Inversion Rules Are Not A Deal-Breaker For AbbVie Inc Benzinga
10:40AM  Tax reform wont bring back billions in cash held abroad: Holtz-Eakin Yahoo Finance
10:28AM  AstraZeneca Hurt As Obama Tries To Get Tough On Tax Inversions at Forbes
10:24AM  [video] Treasury Secretary Jacob Lew Unveils Steps to Curb Tax Inversions at TheStreet
10:01AM  Why AbbVie (ABBV) Stock Is Down Today at TheStreet
09:06AM  Cracking down on inversions CNBC
09:06AM  [video] Cracking down on inversions at CNBC
08:54AM  Global Tensions and Fear Zacks
08:03AM  Investors watch Syria; Lew rewrites inversion rules; Apple's Beats go on? Hot Stock Minute
07:45AM  US STOCKS-Futures lower after U.S. strikes in Syria; inversion moves Reuters
04:26AM  Shire, AstraZeneca fall in London after U.S. tax move at MarketWatch
12:00AM  U.S. Tries to Limit Tax-Cut Deals With Inversion Crackdown Bloomberg
12:00AM  Lew Tries to Limit Tax-Cut Deals With Inversion Crackdown Bloomberg
22-Sep-14 07:58PM  Corporate inversions mean tax hit for shareholders at USA TODAY
01:03PM  3 Stocks Pulling The Drugs Industry Downward at TheStreet
08:00AM  AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting PR Newswire
19-Sep-14 02:30PM  AbbVie (ABBV) Declares 42c Quarterly Dividend at TheStreet
02:08PM  AbbVie Declares Quarterly Dividend PR Newswire
18-Sep-14 06:14AM  AbbVie call buyers back for more optionMONSTER
17-Sep-14 06:51PM  [$$] FDA Panel Recommends More Study on Testosterone Drugs at The Wall Street Journal
04:58PM  FDA panel backs limiting use of testosterone replacement drugs Reuters
12:52PM  Video: Gilead Stock Falls On These Drug Setbacks at Investor's Business Daily
12:52PM  Gilead Stock Is Falling On These Drug Setbacks at Investor's Business Daily
16-Sep-14 03:46PM  AbbVie Sued by Pension Fund Over $54.5 Billion Shire Deal at Bloomberg
01:57PM  Gilead Up As Analyst Lifts Sovaldi Q3 Estimate at Investor's Business Daily
11:36AM  Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
11:36AM  Valeant, Allergan Settle Suit, Allow Shareholder Vote at Investor's Business Daily
07:26AM  EU mergers and takeovers (Sept 16) Reuters
15-Sep-14 04:50PM  Biogen/AbbVie Report Positive Data on MS Drug Zinbryta Zacks
09:26AM  Shire eating disorder drug gets U.S. priority review Reuters
07:13AM  Hynes Keller & Hernandez, LLC Announces Investigation of World Acceptance Corp., PTC, Inc. and AbbVie Inc. PR Newswire
12-Sep-14 05:36PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:05PM  AbbVie's Humira Positive in Phase III Skin Disease Study Zacks
07:30AM  Detailed Results from Biogen Idec and AbbVies Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) Business Wire
06:45AM  AbbVie draws short-term calls optionMONSTER
11-Sep-14 04:15PM  Seattle Genetics-Genmab Expand Deal for Antibody Platform Zacks
07:59AM  The Zacks Analyst Blog Highlights: AbbVie, Infinity Pharmaceuticals, Keryx Biopharmaceuticals, Gilead and Amgen Zacks
03:00AM  AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease PR Newswire
10-Sep-14 02:05PM  Top U.S. Senate Democrats unveil earnings stripping plan Reuters
10:17AM  Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval Zacks
04:17AM  S&P: Inversions Could Lead to Credit Downgrades at The Wall Street Journal
09-Sep-14 02:21PM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
11:11AM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
01:43AM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
01:02AM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
12:20AM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
08-Sep-14 11:21PM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
08:25PM  [$$] Federal Trade Commission Sues AbbVie, Other Drug Companies at The Wall Street Journal
05:50PM  [video] Inversion crackdown all talk, no action? at CNBC
05:02PM  FTC Sues Drug Makers Over Pay-To-Delay Deals at The Wall Street Journal
04:44PM  FTC Sues Drug Makers Over Pay-To-Delay Deals at The Wall Street Journal
04:20PM  [$$] FTC Sues AbbVie, Other Drug Companies at The Wall Street Journal
04:02PM  AbbVie, Teva broke law in AndroGel "pay for delay" deal, U.S. says Reuters
03:52PM  [$$] FTC Sues AbbVie, Other Drug Companies at The Wall Street Journal
03:52PM  Federal Trade Commission Sues AbbVie, Other Drug Companies The Wall Street Journal
02:53PM  FTC sues AbbVie, Teva over generic AndroGel AP
02:04PM  AbbVie, Teva Sued by FTC Over Delay in Generic AndroGel at Bloomberg
01:41PM  [$$] FTC Sues AbbVie, Other Drug Companies at The Wall Street Journal
01:02PM  Pharmacyclics Price Target Cut On Higher Spending at Investor's Business Daily
12:44PM  US FTC says AbbVie, Teva broke law in reaching AndroGel agreement Reuters
09:42AM  [video] Faber Report: Jack Lew speaks out at CNBC
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOMar 04Sale51.204,799245,706395,403Mar 04 05:13 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 03Sale50.034,143207,284273,585Mar 04 05:18 PM
SALEKI-GERHARDT AZITASVP, OperationsMar 03Sale50.252,443122,76085,828Mar 04 05:17 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 03Sale50.223,948198,259180,068Mar 04 05:12 PM
ALBAN CARLOSEVP, Commercial OperationsMar 03Sale50.092,882144,356205,138Mar 04 05:10 PM
HURWICH THOMAS A.VP, ControllerFeb 18Option Exercise44.939,138410,57061,016Feb 19 05:33 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCFeb 18Option Exercise43.218,928385,779256,224Feb 19 05:35 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 18Sale51.2346523,82283,913Feb 19 05:35 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 10Option Exercise45.061,46666,05865,856Feb 12 04:49 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Sale47.8468732,86664,390Feb 07 05:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 05Sale47.781,46069,76385,470Feb 07 05:08 PM